Rx Clinical Program 2026–2027

The systemic administration of Kynurenic Acid (KynA) represents a groundbreaking approach in the treatment of systemic fibrotic conditions. Currently in clinical trials, this method delivers KynA directly into the bloodstream, providing a systemic approach designed to maximize the therapeutic potential of KynA, offering hope for comprehensive treatment strategies in organ fibrotic diseases.

Combining systemic administration of KynA with a one-time delivery of APCs, BirchBioMed is developing a pioneering therapeutic approach tailored for specific autoimmune conditions like Type 1 Diabetes and Alopecia Areata. This innovative strategy, currently in clinical trials for two indications, employs dual-action therapy to directly modulate the autoimmune response. AI-001 aims to recalibrate the immune system, potentially offering a transformative solution for managing and treating certain complex subsets of clinical autoimmune conditions.